Bayer's $1.1 Bil. Chiron Diagnostics Buy Adds Blood Gas Analyzer Line
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of Chiron Diagnostics for $1.1 bil. provides Bayer with an entry into the blood gas analysis market, broadens clinical laboratory systems offerings and will accelerate development efforts in the field of nucleic acid diagnostics.
You may also be interested in...
Versant HIV-1 Assay Approval Could Cut Lab Labor In Half – Bayer
Bayer Diagnostics' Versant HIV-1 RNA 3.0 assay is the first viral load test approved by FDA that can detect any clinically significant change in HIV-1 in one test-run, the company claims
Versant HIV-1 Assay Approval Could Cut Lab Labor In Half – Bayer
Bayer Diagnostics' Versant HIV-1 RNA 3.0 assay is the first viral load test approved by FDA that can detect any clinically significant change in HIV-1 in one test-run, the company claims
Bayer Bolsters Nucleic Acid Diagnostics Portfolio With VGI Acquisition
Bayer Diagnostics will gain the only FDA-approved HIV sequencing resistance test available in the U.S. through its roughly $60 mil. cash acquisition of Visible Genetics, Inc